GSK Acquires Clinical-Stage Biotech Nuvalent for $10.6 Billion in Cash
GlaxoSmithKline announced on June ninth that it will acquire Boston-based Nuvalent for ten point six billion dollars. Nuvalent develops targeted therapies for lung cancer, specifically two late-stage drugs called zidesamtinib and neladalkib. GSK will pay one hundred twenty-four dollars per share, representing a forty percent premium above Nuvalent's recent closing price. This is GSK's third major acquisition in the first half of twenty twenty-six, following deals for RAPT Therapeutics and thirty-five Pharma. The acquisition reflects intense competition among major pharmaceutical companies to acquire promising late-stage biotech assets as they face significant patent expirations. Analysts say the deal strengthens GSK's oncology pipeline and supports its ambitious goal to exceed forty billion pounds in sales by twenty thirty-one. The acquisition is expected to be accretive to core profits starting in twenty twenty-seven.
Key facts
- GSK agreed to acquire Nuvalent for $10.6 billion announced June 9, 2026
- Purchase price of $124 per share represents 40 percent premium to last closing price and 26 percent premium to 30-day average
- Nuvalent develops zidesamtinib and neladalkib, two late-stage targeted therapies for non-small cell lung cancer
- This is GSK's third major acquisition in 2026, after RAPT Therapeutics and 35Pharma
- Net investment for GSK is approximately $9.4 billion after accounting for cash acquired
- Biopharma M&A in 2026 reached $106 billion across 201 deals in first half of year
- Large pharma companies face over $230 billion in revenue at risk from patent expirations by 2030
Limits of this briefing
Available reporting on this deal comes primarily from centrist business and scientific outlets; explicit left and right-leaning media perspectives on this specific acquisition were not found. Some general concerns exist about pharmaceutical consolidation reducing innovation, but these were not prominently featured in coverage of the GSK-Nuvalent deal specifically.
Sources
- GeneOnline News: GSK Bolsters Oncology Portfolio With $10.6 Billion Nuvalent Acquisition in its Third Major Deal in 2026 Centre
- STAT News: GSK to buy Nuvalent, maker of targeted cancer drugs, for $10.6B Centre
- CNBC: Biotech M&A hits $106 billion, on track for best year since pre-Covid Centre
- GuruFocus: GSK Acquires Nuvalent for $10.6 Billion in Cash Centre
- Pharmaceutical Technology: GSK Acquires Nuvalent for $10.6 Billion in Lung Cancer Push Centre